Skip to Content
Merck
CN
  • Mycophenolate mofetil for the management of autoimmune bullous diseases.

Mycophenolate mofetil for the management of autoimmune bullous diseases.

Dermatologic clinics (2011-09-20)
Marina Eskin-Schwartz, Michael David, Daniel Mimouni
ABSTRACT

Immunosuppressive agents such as azathioprine, cyclophosphamide, and mycophenolate mofetil (MMF) are now widely used in the treatment of autoimmune bullous diseases. This article reviews the use of MMF for the treatment of several bullous conditions, and assesses the evidence gathered from clinical trials and case series. According to numerous case series, MMF could be of value in treating refractory disease. The few randomized clinical trials conducted to date of patients with pemphigus and bullous pemphigoid report a similar efficacy for MMF to other immunosuppressants.

MATERIALS
Product Number
Brand
Product Description

Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
USP
Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard
Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard